相关实验视频
Updated: Sep 9, 2025
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
347
三类化合物及其衍生物:治疗关节炎的新兴药物
Zihan Chen1, Ka Fai Leong2, Yuhan Xie1
1School of Pharmacy, Macau University of Science and Technology, Macau SAR, 999078, China.
Mini reviews in medicinal chemistry
|September 5, 2025
概括
作为治疗关节炎,包括类风湿性关节炎 (RA) 和骨关节炎 (OA) 的天然抗炎药物,triterpenoids具有前景. 进一步研究这些化合物可能会导致新的关节炎治疗方法.
科学领域:
- 药理学和天然产品化学
- 免疫学和炎症研究
- 风湿学和肌肉骨疾病
背景情况:
- 关节炎,包括类风湿性关节炎 (RA) 和骨关节炎 (OA),是一个严重的全球性健康问题.
- 现有的关节炎治疗方法往往有局限性,
- 三聚类是一种天然化合物,具有多种生物活性和药理作用,使其成为药物开发的潜在候选物.
研究的目的:
- 提供三类药物及其衍生物作为潜在的治疗类药物,用于治疗类风湿性关节炎 (RA) 和类骨关节炎 (OA).
- 探索三类药物在关节炎治疗中的抗炎和免疫调节特性.
- 在关节炎的背景下讨论三类药物的化学和药理特性和治疗机制.
主要方法:
- 关于三类药物及其衍生物的科学研究的综合文献审查.
- 对三类药物的抗炎和免疫调节机制的研究分析.
- 在临床前和临床关节炎模型中评估与三类药物的疗效相关的药理数据.
主要成果:
- 三类和它们的衍生物具有显著的抗炎和免疫调节特性.
- 已经确定了三类药物对关节炎的治疗益处的各种机制,包括细胞因子产生和细胞信号通路的调节.
- 证据表明,三类药物在治疗关节炎症状和疾病进展方面具有有利的潜力.
结论:
- 三类药物及其衍生物是开发新型抗关节炎药物的有前途的化合物.
- 它们已确定的抗炎和免疫调节作用为它们在类风湿性关节炎 (RA) 和骨关节炎 (OA) 的治疗应用提供了强有力的基础.
- 继续研究基于三类药物的疗法有可能改善关节炎患者的治疗结果.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
230
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
230
01:29Inflammatory Bowel Disease IV: Pharmacological Management
177
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
177
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
200
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
200
01:26Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
01:19Antiasthma Drugs: Leukotriene Modifiers
453
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
453